{"id":55071,"date":"2023-03-22T12:03:28","date_gmt":"2023-03-22T11:03:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/devics-syndrome-treatment-global-market-report-2022-soliris-eculizumab-to-foster-growth-in-the-sector-researchandmarkets-com\/"},"modified":"2023-03-22T12:03:28","modified_gmt":"2023-03-22T11:03:28","slug":"devics-syndrome-treatment-global-market-report-2022-soliris-eculizumab-to-foster-growth-in-the-sector-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/devics-syndrome-treatment-global-market-report-2022-soliris-eculizumab-to-foster-growth-in-the-sector-researchandmarkets-com\/","title":{"rendered":"Devic’s Syndrome Treatment Global Market Report 2022: Soliris (Eculizumab) to Foster Growth in the Sector – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Devic’s Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nDevic’s syndrome (Neuromyelitis optica) treatment accounted for a market value of US$ 217.7 Mn in 2021 and projected to grow at a CAGR of 12.0% during the forecast period from 2022 to 2030.\n<\/p>\n

\nSoliris (Eculizumab) will aid the significant growth of Devic’s Syndrome treatment market throughout the forecast period<\/strong>\n<\/p>\n

\nSoliris (Eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic s syndrome. Patients suffering with Devic’s syndrome possess AQP4 antibody-positive, the body s immune system can turn against itself to produce autoantibodies against AQP4.\n<\/p>\n

\nActivation of anti-AQP4 autoantibodies leads to damage of vital cells in the CNS assisting further demyelination and death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in Devic s syndrome treatment pipeline such as Satralizumab – Phase 3 (Hoffmann-La Roche\/ Chugai Pharmaceutical), MEDI-551- Phase 2\/3 (MedImmune LLC), and RC18 – Phase 3 (RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on 15 October 2020; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).\n<\/p>\n

\nNorth America dominated the overall global market specifically due to recent drug approval, promising drugs in pipeline, and developed diagnostic landscape<\/strong>\n<\/p>\n

\nIn 2021, North America dominated the market and anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirement for target-specific molecules to treat Devic s Syndrome, and easy adaptability & accessibility for newly launched drug. According to National Multiple Sclerosis Society, there are around 4,000 people suffering with Devic’s syndrome in the United States with majority of women population. Asia Pacific will grow during the forecast period from 2022 to 2030, due to increasing awareness related to Devic s Syndrome assisting the rise in diagnosis & treatment rate in patients suffering with rare diseases.\n<\/p>\n

\nMarket Segmentation<\/strong>\n<\/p>\n

\nDrugs<\/strong>\n<\/p>\n